Tags

Type your tag names separated by a space and hit enter

[A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection].
Korean J Hepatol 2008; 14(4):513-8KJ

Abstract

The wide use of lamivudine in chronic hepatitis B has produced a monotonic increase in patients with lamivudine resistance. Therefore, treating lamivudine resistance in chronic hepatitis B is a major concern in clinical practice for the treatment of hepatitis B virus (HBV). There is conflicting evidence on the outcome of pegylated interferon alpha (PEG-IFN alpha) therapy against lamivudine-resistant HBV, which is due to mutations in the YMDD motif. We experienced a patient with chronic hepatitis B who was successfully treated with PEG-IFN alpha-2a after the development of virologic and biochemical breakthrough during lamivudine therapy. Virologic breakthrough was associated with the emergence of YMDD mutants 48 months after starting lamivudine therapy. Treatment with PEG-IFN alpha-2a for 12 months resulted in an undetectable serum level of HBV DNA and the resolution of hepatitis, and the virologic response was maintained over 16 months after cessation of PEG-IFN alpha-2a.

Authors+Show Affiliations

Department of Internal Medicine, College of Medicine, The Catholic University of Korea, WHO Collaborating Center of Viral Hepatitis, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

kor

PubMed ID

19119246

Citation

Hur, Won Haing, et al. "[A Case Report of Treatment With Pegylated Interferon Alpha for Lamivudine-resistant Chronic Hepatitis B Virus Infection]." The Korean Journal of Hepatology, vol. 14, no. 4, 2008, pp. 513-8.
Hur WH, Woo HY, Jeong SW, et al. [A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection]. Korean J Hepatol. 2008;14(4):513-8.
Hur, W. H., Woo, H. Y., Jeong, S. W., You, C. R., Bae, S. H., Choi, J. Y., & Yoon, S. K. (2008). [A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection]. The Korean Journal of Hepatology, 14(4), pp. 513-8. doi:10.3350/kjhep.2008.14.4.513.
Hur WH, et al. [A Case Report of Treatment With Pegylated Interferon Alpha for Lamivudine-resistant Chronic Hepatitis B Virus Infection]. Korean J Hepatol. 2008;14(4):513-8. PubMed PMID: 19119246.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection]. AU - Hur,Won Haing, AU - Woo,Hyun Young, AU - Jeong,Soung Won, AU - You,Chan Ran, AU - Bae,Si Hyun, AU - Choi,Jong Young, AU - Yoon,Seung Kew, PY - 2009/1/3/entrez PY - 2009/1/3/pubmed PY - 2009/4/1/medline SP - 513 EP - 8 JF - The Korean journal of hepatology JO - Korean J Hepatol VL - 14 IS - 4 N2 - The wide use of lamivudine in chronic hepatitis B has produced a monotonic increase in patients with lamivudine resistance. Therefore, treating lamivudine resistance in chronic hepatitis B is a major concern in clinical practice for the treatment of hepatitis B virus (HBV). There is conflicting evidence on the outcome of pegylated interferon alpha (PEG-IFN alpha) therapy against lamivudine-resistant HBV, which is due to mutations in the YMDD motif. We experienced a patient with chronic hepatitis B who was successfully treated with PEG-IFN alpha-2a after the development of virologic and biochemical breakthrough during lamivudine therapy. Virologic breakthrough was associated with the emergence of YMDD mutants 48 months after starting lamivudine therapy. Treatment with PEG-IFN alpha-2a for 12 months resulted in an undetectable serum level of HBV DNA and the resolution of hepatitis, and the virologic response was maintained over 16 months after cessation of PEG-IFN alpha-2a. SN - 1738-222X UR - https://www.unboundmedicine.com/medline/citation/19119246/[A_case_report_of_treatment_with_pegylated_interferon_alpha_for_lamivudine_resistant_chronic_hepatitis_B_virus_infection]_ L2 - http://www.diseaseinfosearch.org/result/3332 DB - PRIME DP - Unbound Medicine ER -